TipRanks identified the corporate insiders with the best-performing track records and the stocks they are buying. » Read More
Judge Edgardo Ramos in Manhattan dismissed Express Scripts' claim that Anthem breached an implied covenant of good faith and fair dealing. » Read More
John Rountree, partner at Novasecta, discusses how the pharmaceutical industry is reacting to U.S. President Donald Trump's delayed health care bill. » Read More
David Maris, Wells Fargo Securities talks about the pharma space as pricing pressure rekindles fears in the industry.
The ruling for Mumia Abu-Jamal may lead to similar decisions in favor of other infected prisoners, which could strain prison budgets.
CNBC's Meg Tirrell reports the cost of a drug that can reverse an opioid overdose is rising.
These are the stocks posting the largest moves after the bell.
CNBC's Meg Tirrell reports the latest on the war on drug prices as several drugs are seeing their prices hiked since the start of the year.
As President-elect Trump scolds companies offshoring production, these top federal contractors are closely following his Twitter feed.
Bill Ackman turned on Mike Pearson, replacing him with Joe Papa hoping that Valeant could be turned around, The New York Times reports.
Olav Hellebo, CEO at ReNeuron, discusses the value of stem cell treatment as well as investment in his research area.
These are the stocks posting the largest moves after the bell on Thursday, including: Mylan, Lockheed Martin and more.
CNBC's Meg Tirrell reports that one analyst is raising a red flag on Biogen due to the incredibly high price of a new drug to treat a rare genetic disease in children.
Morgan Stanley presents its top health-care stock ideas for 2017.
John Rountree, managing partner at Novasecta, discusses his expectations of the pharma space in 2017.
Donald Trump is unlikely to be as tough on pharmaceuticals as Hillary Clinton would have been, says Raghuram Selvaraju at Rodman & Renshaw.
David Nelson, Belpointe asset management, and Luke Timmerman, Timmerman Report, forecast 2017 trends in biotech and if the space is something to consider for your portfolio.
Ronny Gal, Sanford C. Bernstein analyst, shares his expectations on the biotech sector in 2017.
CNBC's Meg Tirrell takes a look at what investors can expect from the biotech and pharma sectors in the new year.
Beijia Ma, equity strategist at BofA Merrill Lynch, explains the nuances of the autonomous vehicle market, adding that sensor technology is crucial to its success.
Michael Yee, RBC Capital Markets, and Michael King, JMP Securities, look back at a very rough year for biotech stocks and discuss whether the sector is primed to take off.
Tim Chiang, BTIG, weighs in on the healthcare sector under a Trump presidency.
Synergy Pharmaceuticals skyrocketed after the firm reported positive trial results for an irritable bowel syndrome drug.
Get the best of CNBC in your inbox